TY  - JOUR
AU  - Tap, William D
AU  - Gelderblom, Hans
AU  - Palmerini, Emanuela
AU  - Desai, Jayesh
AU  - Bauer, Sebastian
AU  - Blay, Jean-Yves
AU  - Alcindor, Thierry
AU  - Ganjoo, Kristen
AU  - Martin-Broto, Javier
AU  - Ryan, Christopher W
AU  - Thomas, David M
AU  - Peterfy, Charles
AU  - Healey, John H
AU  - van-de-ande, Michiel
AU  - Gelhorn, Heather L
AU  - Shuster, Dale E
AU  - Wang, Qiang
AU  - Yver, Antoine
AU  - Hsu, Henry H
AU  - Lin, Paul S
AU  - Tong-Starksen, Sandra
AU  - Stacchiotti, Silvia
AU  - Wagner, Andrew J
PY  - 2019
DO  - 10.1016/S0140-6736(19)30764-0
UR  - http://hdl.handle.net/10668/14158
T2  - Lancet (London, England)
AB  - Background: Tenosynovial giant cell tumour (TGCT), a rare, locally aggressive neoplasm , overexpresses colony-stimulating factor 1 (CSF1). Surgery is standard with no approved systemic therapy . We aimed to evaluate pexidartinib, a CSF1 receptor...
LA  - en
PB  - The Lancet Publishing Group
KW  - Antineoplastic Agents
KW  - Double-Blind Method
KW  - Intention to Treat Analysis
KW  - Young Adult
KW  - Treatment Outcome
KW  - Adult
KW  - Aged
KW  - Female
KW  - Giant Cell Tumor of Tendon Sheath
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Protein Kinase Inhibitors
KW  - Response Evaluation Criteria in Solid Tumors
KW  - Survival Analysis
TI  - Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.
TY  - research article
VL  - 394
ER  -